Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break
As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up.
A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.
The piece centers on a dynamic that many teams recognize once they’re in it… early workflows are built for speed and feasibility, often relying on fresh leukapheresis-derived material because it’s practical and widely understood. But as programs expand, patient populations grow and sites of care spread out geographically, and what used to be handled through direct coordination starts to strain under the pressures of scale.
This is where the conversation around the cryopreservation of starting materials tends to resurface as an approach to decoupling collections from manufacturing. In practice, many programs evolve over time, starting with fresh workflows and transitioning as the limitations become harder to ignore.
You can read the full article here:
